Abstract
Mepolizumab is a humanized monoclonal antibody that binds specifically to and inactivates a protein cell messenger termed IL-5, which plays a major role in the proliferation, maturation, activation and survival of eosinophils. As a result, mepolizumab has been studied in a number of eosinophil-associated diseases, such as asthma, hypereosinophilic syndrome and eosinophilic esophagitis (EE). EE is a clinical entity characterized by eosinophilic infiltration of the esophagus (≥15 eosinophils/high power field in one or more fields) in the absence of gastroesophageal reflux. EE is on the rise, and this can not be fully accounted for by increased recognition. Currently, available therapies, although successful in many cases, can be disappointing in some patients, whether from lack of response, negative impact on quality of life, or significant toxicity. In order to better define EE therapy, investigators are evaluating novel drugs, including anti-IL-5 agents such as mepolizumab. Mepolizumab has been demonstrat...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
